What are the risks of psychedelic therapy and how do you stay safe?

Psychedelic therapy carries genuine risks — physical, psychological, and relational — and the literature is clear that these risks are not uniformly distributed. They depend heavily on who is receiving the substance, under what conditions, and with what preparation and integration support. Understanding the difference between intrinsic and extrinsic risk is the first step toward an honest assessment.

Physical risks: narrower than commonly assumed

Stanislav Grof, whose clinical research with LSD spans decades, is direct on the pharmacological question: pharmaceutically pure LSD is, from a biological standpoint, a surprisingly safe substance. Laboratory examinations — EEG, ECG, blood count, liver function — show no pathological changes even after extended series of sessions. The major physiological danger is not the drug itself but the intensity of the emotions it triggers. This changes the screening calculus considerably. Grof identifies serious cardiovascular conditions — arteriosclerosis, malignant hypertension, vascular aneurysms, history of myocardial infarction — as the primary somatic contraindications, because the risk is not pharmacotoxic but hemodynamic: extreme emotional arousal places demands on the cardiovascular system that some bodies cannot safely meet. Pregnancy is an absolute contraindication. Epileptic disposition warrants individual evaluation, since LSD can occasionally trigger status epilepticus, though certain seizure types have responded favorably to treatment (Grof, 1980).

The same caution applies to street substances. Grof notes that samples sold outside clinical settings have been found to contain amphetamines, strychnine, PCP, and other adulterants physiologically far more dangerous than LSD itself — a reminder that the safety profile of clinical research does not transfer to uncontrolled settings.

Psychological risks: the more serious terrain

The emotional risks are where the literature converges most urgently. Grof is unambiguous:

"I have never seen adverse after-effects of an LSD session in an individual who did not have considerable emotional problems prior to the session."

This is not a reassurance — it is a diagnostic principle. The degree of psychological safety is critically dependent on the pre-session emotional balance of the subject and on the external circumstances. For individuals with borderline psychotic symptoms, a history of psychotic episodes, or severe interpersonal maladjustment, the risk of triggering transient psychotic states, aggressive behavior, or suicidal ideation is real and must be weighed carefully. Unresolved unconscious material that remains unintegrated after a session can intensify pre-existing symptoms, produce new symptom sets, or generate flashbacks.

Rick Strassman's DMT research adds a dimension that is easy to underestimate: after high doses, volunteers were "extraordinarily suggestible, open, and vulnerable," which placed enormous ethical demands on the therapeutic relationship. The line between support and suggestion — between helping someone process what arose and telling them what it meant — is thin and consequential (Strassman, 2001).

The defensive use of the numinous

A subtler risk, named by Kalsched, is the one the psychedelic renaissance tends to underplay. Many people who seek psychedelic experiences are running a pneumatic logic — if I am spiritual enough, if I achieve union with the Divine, I will not suffer. Psychedelics can deliver exactly this: states of ecstatic rapture, feelings of cosmic unity, dissolution of ego boundaries. The problem is that these states can be used defensively. Kalsched observes that many troubled people are "positively addicted to the positive, light-giving side of numinous experience," seeking it to escape the pain of becoming a "limited, time-bound, mortal, definite, embodied individual" (Kalsched, 1996). The numinous experience does not automatically integrate; it can be used to bypass the very material it was supposed to illuminate. Mahr (2020), writing from a Jungian perspective, names this directly: the ego can trivialize spiritual experiences and use a shallow search for superficial religious encounters defensively, turning psychedelic work into recreation rather than genuine depth.

Strassman's clinical observation cuts to the same point: most volunteers hoped for a final resolution to questions about why they were born, or a union with the Divine in which all conflict ended. DMT gave them "the trip they needed, rather than the one they wanted."

How safety is actually built

The literature converges on several conditions that are not optional:

Set and setting. The psychological state the person brings and the physical and relational environment in which the session occurs are the primary determinants of outcome — more than dosage, more than the specific substance.

Screening. Careful pre-session evaluation for both somatic and psychological contraindications is essential. Under research conditions with limited sessions and no inpatient backup, individuals with borderline psychotic presentations must be screened out. Under optimal conditions with experienced teams and open-ended treatment, the range of who can safely participate widens considerably.

Preparation and integration. The session itself is not the therapy. Van der Kolk (2014) notes that psychedelic substances are powerful agents with a troubled history and can easily be misused through careless administration and poor maintenance of therapeutic boundaries. The MDMA research he cites — 83 percent of assault survivors no longer meeting PTSD criteria after treatment, versus 25 percent in the placebo group — was conducted with extensive pre- and post-session psychotherapy. The integration work is where the material becomes metabolizable.

Therapist qualification. Strassman argues that having undergone psychedelic experience oneself should be a prerequisite for administering these substances to others, alongside formal supervised training in self-examination. The power differential in the room after a high dose is extreme; the therapist's own unexamined material will enter the field.

The honest summary is that psychedelic therapy, properly conducted, carries manageable risk for most people and significant risk for some. The conditions that make it safe — rigorous screening, experienced guides, genuine integration work, and a therapeutic frame that does not promise transcendence — are also the conditions most likely to be absent when the work is done outside clinical or ceremonial containers.

  • individuation — Jung's term for the lifelong process of becoming a whole self, the psychological context in which psychedelic experiences are often interpreted
  • shadow — the unconscious dimension of the psyche that psychedelic states frequently constellate, for better and worse
  • Donald Kalsched — depth psychologist whose work on trauma and the archetypal self-care system illuminates the defensive uses of numinous experience
  • Stanislav Grof — psychiatrist and researcher whose decades of clinical LSD work remain the most systematic account of psychedelic risk and method

Sources Cited

  • Grof, Stanislav, 1980, LSD Psychotherapy: The Healing Potential of Psychedelic Medicine
  • Strassman, Rick, 2001, DMT: The Spirit Molecule
  • Kalsched, Donald, 1996, The Inner World of Trauma
  • Mahr, Greg, 2020, Psychedelic Drugs and Jungian Therapy
  • Van der Kolk, Bessel, 2014, The Body Keeps the Score